Dave Knapp

So, so what you've seen Eli Lilly and Novo do in response to this secondary market that has popped up to ultimately has it, has it increased accessibility because there's shortages? Absolutely. It has fulfilled its, its dutiful responsibility as designed within the code of the U S law. But what it's also done is it's,

So, so what you've seen Eli Lilly and Novo do in response to this secondary market that has popped up to ultimately has it, has it increased accessibility because there's shortages? Absolutely. It has fulfilled its, its dutiful responsibility as designed within the code of the U S law. But what it's also done is it's,

So, so what you've seen Eli Lilly and Novo do in response to this secondary market that has popped up to ultimately has it, has it increased accessibility because there's shortages? Absolutely. It has fulfilled its, its dutiful responsibility as designed within the code of the U S law. But what it's also done is it's,

added a level of competition that usually doesn't exist for drugs that are under a patent. And because it did this, it forced Eli Lilly and Novo Nordisk to look at this a different way. So what they decided to do is they decided to say, we're going to cut out the PBMs altogether, which is actually a very bold move for pharmaceutical companies to make because

added a level of competition that usually doesn't exist for drugs that are under a patent. And because it did this, it forced Eli Lilly and Novo Nordisk to look at this a different way. So what they decided to do is they decided to say, we're going to cut out the PBMs altogether, which is actually a very bold move for pharmaceutical companies to make because

added a level of competition that usually doesn't exist for drugs that are under a patent. And because it did this, it forced Eli Lilly and Novo Nordisk to look at this a different way. So what they decided to do is they decided to say, we're going to cut out the PBMs altogether, which is actually a very bold move for pharmaceutical companies to make because

Pharmaceutical companies have always seen PBMs as their customers, right? We sell to the PBMs. The PBMs then put it on the formularies and doctors prescribe it based upon what's on the formula. How many times have you gone to the doctor, people who are watching, and the doctor says to you, let's see, you have this. So here's the four or five antibiotics I could prescribe.

Pharmaceutical companies have always seen PBMs as their customers, right? We sell to the PBMs. The PBMs then put it on the formularies and doctors prescribe it based upon what's on the formula. How many times have you gone to the doctor, people who are watching, and the doctor says to you, let's see, you have this. So here's the four or five antibiotics I could prescribe.

Pharmaceutical companies have always seen PBMs as their customers, right? We sell to the PBMs. The PBMs then put it on the formularies and doctors prescribe it based upon what's on the formula. How many times have you gone to the doctor, people who are watching, and the doctor says to you, let's see, you have this. So here's the four or five antibiotics I could prescribe.

And this is the one your insurance company likes. They like it because they get kickbacks, right? They decided to just go around them all together. And so now Eli Lilly and Novo Nordisk both have direct to patient programs that offer a cash pay price that just cuts insurance out of the whole deal.

And this is the one your insurance company likes. They like it because they get kickbacks, right? They decided to just go around them all together. And so now Eli Lilly and Novo Nordisk both have direct to patient programs that offer a cash pay price that just cuts insurance out of the whole deal.

And this is the one your insurance company likes. They like it because they get kickbacks, right? They decided to just go around them all together. And so now Eli Lilly and Novo Nordisk both have direct to patient programs that offer a cash pay price that just cuts insurance out of the whole deal.

And they charge 400 and basically it's a little bit more convoluted than this, but for all intents and purposes, it's $499 a month for all the doses of Wegovy. And up to the 10 milligram of Zepbound, which is the weight loss version of this one, $499 a month, right? For the single dose vial versions.

And they charge 400 and basically it's a little bit more convoluted than this, but for all intents and purposes, it's $499 a month for all the doses of Wegovy. And up to the 10 milligram of Zepbound, which is the weight loss version of this one, $499 a month, right? For the single dose vial versions.

And they charge 400 and basically it's a little bit more convoluted than this, but for all intents and purposes, it's $499 a month for all the doses of Wegovy. And up to the 10 milligram of Zepbound, which is the weight loss version of this one, $499 a month, right? For the single dose vial versions.

they've done this because they're able to then forget about what the PBMs have to get paid in this, and they just offer it at a direct cash pay price for $4.99. Still a lot higher.

they've done this because they're able to then forget about what the PBMs have to get paid in this, and they just offer it at a direct cash pay price for $4.99. Still a lot higher.

they've done this because they're able to then forget about what the PBMs have to get paid in this, and they just offer it at a direct cash pay price for $4.99. Still a lot higher.

Correct. In a sense, yes. That's novel, too.

Correct. In a sense, yes. That's novel, too.